Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-2 for CD25 Positive Hairy Cell Leukemia
NCT00321555Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Aug 2016
- Modality
- Immunotoxins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LMB-2 in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Primary endpoint: Number of Patients Who Obtain Partial Response/Complete Remission at 6 months. Started May 2006; status: completed.
02
Drugs
LMB-2
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT00321555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321555.